AbbVie Inc. decided to terminate its collaboration agreement with Assembly Biosciences Inc. on microbiome gastrointestinal programs.

The decision is not based on any efficacy, safety, or other data related to the collaboration programs, Assembly Biosciences noted in a June 18 news release.

Assembly Biosciences will regain worldwide rights to all microbiome gastrointestinal development programs licensed to Allergan PLC — which was acquired by AbbVie in May for $63 billion — under the 2017 deal.

The research, development, collaboration and license agreement included experimental therapy ABI-M201 for the treatment of ulcerative colitis and ABI-M301, which is still in preclinical development for Crohn's disease.

Assembly Biosciences expects the transition to close in the fourth quarter, while AbbVie will continue to fulfill its obligations during the 120-day transition period.

The South San Francisco, Calif.-based company, which develops oral therapies for the treatment of hepatitis B virus, will explore strategic alternatives for the microbiome franchise, according to the news release.

Assembly Biosciences said it expects no change to its projected cash runway and its cash, cash equivalents and investments will be sufficient to fund operations into 2022.